- Home
- NAVI vs EXEL Comparison
NAVI vs EXEL Comparison
Compare NAVI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAVI | EXEL |
|---|---|---|
| Founded | 1973 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NAVI | EXEL |
|---|---|---|
| Price | $12.97 | $46.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 24 |
| Target Price | $14.14 | ★ $45.18 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 01-28-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.91% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | $443,000,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | $19.44 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $10.53 | $31.90 |
| 52 Week High | $16.07 | $49.62 |
Technical Indicators
Market Signals| Indicator | NAVI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 70.08 |
| Support Level | $12.90 | $40.83 |
| Resistance Level | $13.48 | $42.09 |
| Average True Range (ATR) | 0.32 | 1.25 |
| MACD | 0.04 | 0.35 |
| Stochastic Oscillator | 62.41 | 90.56 |
Price Performance
Historical ComparisonAbout NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.